Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …

Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world
and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and …

In this study, we comprehensively charted the cellular landscape of colorectal cancer (CRC)
and well-matched liver metastatic CRC using single-cell and spatial transcriptome RNA …

Abstract DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial
assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2 …

Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality
worldwide. Its complexity is influenced by various signal transduction networks that govern …

HER2 is an established therapeutic target in a large subset of women with breast cancer; a
variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab …

Under the selective pressure of therapy, tumours dynamically evolve multiple adaptive
mechanisms that make static interrogation of genomic alterations insufficient to guide …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …